Ambrx Biopharma Inc (AMAM) News

$AMAM $28 APPROVED BJ $JNJ

Shareholders Approve Acquisition by Johnson & Johnson


https://www.globenewswire.com/news-release/2024/03/06/2841709/0/en/Ambrx-Shareholders-Approve-Acquisition-by-Johnson-Johnson.html

I sold, $12.55 - $14 range. No regrets. O'Connor just never looked legit to me. He made off (Madeoff:)) with millions! Mostly from free shares, it seems like. imo. Dropped the funds into another that I tripled down on, and it then doubled when it got bought out the same day as this. No problems, but those two were a nice change from the mistakes I was used to making. Guess I was due.

WOW CONGRAT$ TO CURRENT SHAREHOLDERS (NO WHAMMIES)

$AMAM NEWS https://www.globenewswire.com/news-release/2024/01/08/2805344/0/en/Ambrx-Announces-Sale-to-Johnson-Johnson.html

Message in reply to:
Okay, I've been in since the $2s, and get more nervous by the day, holding. Management seems shady to me, and wondering what timeframe are you thinking before something bad? tia.

Okay, I've been in since the $2s, and get more nervous by the day, holding. Management seems shady to me, and wondering what timeframe are you thinking before something bad? tia.

Does the name Christian Lamarco (www.culperresearch.com) mean anything to you?
If not, you should know that this "activist investor" (aka "short") has requested through FOIA from the FDA for the below information. Prepare for a hit piece and a stock drop.

"Requesting any and all copies of communications between the FDA and Ambrx Inc pertaining to any Breakthrough Therapy designation requests made by Ambrx for its ARX788 candidate."

https://www.fda.gov/media/170006/download

Ah, the smell of a new hedge fund on scene. D.E. Shaw reeks, imo.

Ahh the smell of a 10 bagger stock!!!!

AMAM: And this particular "TODAY" as well, Bro!! WOW!!

Pharma. Amam up 400 percent in month

https://www.barchart.com/stocks/quotes/amam/technical-chart?plot=CANDLE&volume=total&data=DO&density=M&pricesOn=1&asPctChange=0&logscale=0&indicators=BBANDS(20,2);SMA(20);SMA(50);SMA(100);SMA(200);ACCUM;AROONOSC(25);ATR(14);CHKMF(20);STOFA(14,3);MFI(14,100);MACD(12,26,9);RSI(14,100);TRIX(3.3);ADXMOD(14);AROON(25)&sym=amam&grid=1&height=500&studyheight=100

Nice mover.

Huge money maker today. AMAM.

mb

AMAM..................................https://stockcharts.com/h-sc/ui?s=AMAM&p=W&b=5&g=0&id=p86431144783

Always sell these big open gap's!

Nothing but down all day folks.

Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM) today announced encouraging initial data from its ongoing Phase 1 trial (APEX-01 (NCT04662580)) investigating ARX517, Ambrx's proprietary anti-PSMA ADC, in prostate cancer patients. APEX-01 is a Phase 1, first-in-human, open label dose escalation and dose expansion trial enrolling patients with advanced prostate cancer whose tumors have progressed on at least two prior FDA-approved treatments. APEX-01 is the only ongoing clinical trial in the United States targeting PSMA with an ADC. APEX-01 opened for enrollment July 2021 and this is the first data being reported in the study.

In the Phase 1 dose-escalation portion of the study, ascending dose levels of ARX517 is administered as a single agent every 3 weeks. The primary endpoints are safety, tolerability and pharmacokinetics. The key secondary endpoint is objective decline of prostate-specific antigen (PSA) from baseline and/or tumor shrinkage. PSA is a protein produced by the prostate gland and is commonly used as a biomarker to diagnose and follow prostate cancer. A greater-than or equal to 50% reduction in PSA levels from baseline is considered clinically relevant and has been shown to correlate with improved overall survival in prostate cancer.

To date, 22 prostate cancer patients have been dosed across 7 dose level Cohorts starting from 0.32 mg/kg to 2.4 mg/kg. A minimum of 3 patients were enrolled at each Cohort. The dose limiting toxicity (DLT) period is 21 days.

Of 22 patients evaluable for safety, no drug-related severe adverse events (SAEs) or grade greater-than or equal to3 treatment-related AEs have been observed. ARX517 was well-tolerated with grade 1 or 2 treatment-related adverse events being reported. The maximum tolerated dose (MTD) has not yet been reached.PSA reductions of > 30% have been observed in Cohorts 2-5, beginning at the second to lowest dose, 0.64 mg/kg.In Cohort 6 (2.0 mg/kg dose), 3 of 3 (100%) patients experienced a greater than 50% reduction in PSA levels. 2 of 3 patients experienced a greater than 90% reduction of PSA levels. One of three patients had soft tissue measurable disease and experienced a RECIST v1.1 partial response at the first on-treatment scan.Three patients have been dosed in Cohort 7 with no DLTs.

"The preliminary data from patients with prostate cancer are highly encouraging," said Dr. Michael Schweizer, MD, an Investigator on APEX-01 and Associate Professor

Division of Medical Oncology, Fred Hutchinson Cancer Research Center. "Seeing a greater than 50% reduction in PSA levels in three of three patients at the 2.0 mg/kg dose level in this patient population is impressive, and ARX517 appears to be well tolerated so far. I am very optimistic for its future development. We look forward to more data from APEX-01, as the dose escalation continues in this difficult-to-treat patient population."

The Safety Monitoring Committee (SMC) meeting to discuss the next dose Cohort is scheduled for the end of February 2023. Not all patients have undergone or completed tumor assessments and the data are not yet final.

Ambrx plans to report further information regarding ARX517 and the APEX-01 study at its upcoming Analyst and Investor Day scheduled for February 24, 2023. Additional data are planned for presentation at an upcoming medical meeting.

back to 2 dollars??

AMAM: The (trending), 'CANCER-CURE-OF-THE-DAY-STOCK'!!! (Gap-&-Run today, or Gap-&TRAP the other way???)

AMAM is doing well as the game has changed drastically.

$10++?

mb

AMAM will surprise a few of us once trading over $2.15. Hold on tight works.

mb

AMAM going up the hill.

mb

https://www.barchart.com/stocks/quotes/amam/technical-chart?plot=CANDLE&volume=total&data=DO&density=M&pricesOn=1&asPctChange=0&logscale=0&indicators=BBANDS(20,2);SMA(20);SMA(50);SMA(100);SMA(200);ACCUM;AROONOSC(25);ATR(14);CHKMF(20);STOFA(14,3);MFI(14,100);MACD(12,26,9);RSI(14,100);TRIX(3.3);ADXMOD(14);AROON(25)&sym=amam&grid=1&height=500&studyheight=100

AMAM waking up from the $2 resting area.

mb

Happy New Year! AMAM will have one too.

Slow progression up the mountain ?.

mb

Absolutely,just loaded up nother 25 shares.

https://stockcharts.com/h-sc/ui?s=amam&p=D&yr=0&mn=6&dy=0&id=p38090673899

https://www.barchart.com/stocks/quotes/amam/technical-chart?plot=CANDLE&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;SMA(20);SMA(50);SMA(100);SMA(200);CHKMF(20)&sym=CGRA&grid=1&height=210&studyheight=100

https://www.barchart.com/stocks/quotes/amam/opinion

Support 50 DMA $1.09

FDA approval/fast track status is coming right up.

you are right: this is a $50 dollar stock.

This is going to fly $50 FDA lapproval etter waiting and waiting, we may see after the close

Thanks Reena, that is very helpful

AMAM. One to accumulate at $2 if you are lucky.

mb

I just saw your message . I use custom TD scanners I made , I've written scripts for them after using Scanz for about 6 months.(3 years ago) I also use finvz for the short squeeze plays I find on Nasdaq.(Current Trend) If you learn how to build you a scanner you will need more than one. Here's a Tip, create price ranges that are close, like .001-.002 .002-.005 ,.006 -.01 , unusual volume. OTC premarket scanner, (you can see OTC stock that are moving before the market opens). premarket low float gaps for Nasdaq. You want to create a scanner for the price range you are conformable trading in, don't try to jump all over the market . Find a price range and tweak your scanner. Hope that helps. Once you get you a good scanner you won't have to follow people, Your scanner will tell you where the money is. You will have to make changes or create new one because the market changes, You have to adapt. One last thing, Once you start making money open up you a minimum of 3 different broker accounts. You will see the different in information from one broker to the next.

Well than, bring it on! Good day today and many more on tap. Fast track will catapult this pps like you never seen before.

The pattern for most small cap pharma/biotech companies after a positive event in their product line is to sell shares with an S-1 filing
to take advantage of the higher share price since the company will be burning through 100's millions of dollars to move the product through trials.

Yes, I was just recently reading about the fast track system for CDER to pass than FDA Approval. Nice!!!

I think there is news on the way:

They will go for the fast track approval.

$AMAM:

red to green today:

company is not going to pass up the opportunity to get this to fast track approval given the critical need of this drug.

FDA is flexible with critical need cancer drugs that have such a strong profile:

With investors reacting the way they did, it’s safe to say they were impressed with the results; considering how big the breast cancer market is, the drug’s potential has caused a bit of a stir.

Cowen analyst Phil Nadeau also likes what he’s seeing here, noting: "ARX-788 continues to have a good safety profile with no AEs leading to discontinuation or drug-related SAEs. Our consultants have called ARX788's activity in HER2 pretreated patients 'robust' and think that its activity in Enhertu and Kadcyla failures in particular is likely to ensure ARX788 a place in the treatment paradigm."

It should be noted, the results are preliminary and that it is still a mid-stage trial and further Phase 3 testing will be required, although given the strong results, the company might decide to try and fast-track this drug to approval.

Looks terrible again

Cowen and company has a buy rating for this stock.

Buy rating issued on 12/11/22.

news is too damn good to be true bro.

this data is the strongest ever seen for breast cancer.

they will get a fast track status.

and they might sign a deal with a large pharma.


$AMAM is also loaded with a ton of cash.

Ya, Bro your right I was looking at the closing price that said 12/13/2022. But yes, we will
get these Bastards tomorrow.

https://www.marketbeat.com/stocks/NYSE/AMAM/short-interest/
This tells us exactly what is taking place.

these sorry pieces of gutter trash are using tiny sell orders to try to manipulate the stock price.

like 1-2 share sells.

they wont have a place to hide tomorrow morning.

most definitely:

AMAM has become an attractive buyout candidate with this breakthrough cancer drug.

and they have a strong pipeline also.


large pharma could pick them up or partner with them.

If and when we get it, do you see a buy out coming?

we are likely to get a fast track status based on such a strong data.

FDA is flexible now days for these critically needed cancer drugs.

Thanks, I will lock them up ;this is for mr shorty; Fast track is a designation by the United States Food and Drug Administration (FDA) of an investigational drug for expedited review to facilitate development of drugs that treat a serious or life-threatening condition and fill an unmet medical need. Fast Track designation must be requested by the drug company. Wikipedia

Short Interest 4,364 shares - source: NYSE

https://fintel.io/ss/us/amam

it is looking like we are going to have a huge gapper in the morning.


and if there is news tomorrow, this will rocket to $5 in a hurry.

yep. it is best to lock up your shares.

but somewhat close to the actual price.

for example you may wish to put your shares up for sale at around $3.

and just monitor the stock. move up your sale price to $4 as the stock price rises to near $3.

The FDA usually requires a phase III clinical trial before approving a new medication. Due to the larger number of participants and longer duration or phase III, rare and long-term side effects are more likely to show up during this phase